We Venture Capital
VC Fund
We Venture Capital is a VC fund focused on Health Care and Biotechnology. WHO WE ARE We Venture Capital is a global venture capital investor, investing in diagnostics start-ups, as well as digital solutions and biotechnology in the diagnostics arena. We are the corporate venture investment arm of Werfen, a worldwide leader in Specialized Diagnostics. We have an evergreen structure, partnering with early-stage start-upsclose to market entry, or early scale-ups. We believe in technological advancement as a means to improve patient outcomes and revolutionize healthcare. Our headquarters are in Barcelona, Spain WHAT WE DO We support our portfolio companies by leveraging Werfen’s knowledge and tailoring it to each company’s current needs and long-term vision. With our strategic mindset, extensive professional network, and board experience, we fully invest in the creation of a successful outcome. We form lasting partnerships with our portfolio companies and take an active role, often via board engagement.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries We Venture Capital invests in
Stages We Venture Capital invests in
Countries We Venture Capital invests in
Investment Focus
Industry
- Health Care 4 (44%)
- Biotechnology 4 (44%)
- Medical 2 (22%)
- Life Science 2 (22%)
- Home Health Care 1 (11%)
Stage
- Series A 4 (44%)
- Seed 2 (22%)
- Series C 1 (11%)
- Venture - Series Unknown 1 (11%)
Country
- United Kingdom 3 (33%)
- China 1 (11%)
- Spain 1 (11%)
- Canada 1 (11%)
- Sweden 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
AGILINK
|
AGILINK is a high-tech enterprise specializing in the research and development of intelligent robots, committed to combining advanced technologies such as artificial intelligence, automation, and intelligent control systems to deliver innovative robotic solutions for industrial, commercial, and service applications. | $147M / Venture - Series Unknown / Jun 24, 2026 | |
Respiree
|
They offer platforms that are able to report clinical deterioration and provide recommended interventions with post-monitoring.They work in the health care industry, just like you. We take the time to get to know you, and we always keep your best interests in mind when adding and adjusting products in our catalog. | $11.6M / Series A / Jul 23, 2025 | |
Portal Biotech
|
Portal Biotech is a biotechnology company specializing in advanced proteomics and metabolomics through single-molecule detection. | $37.1M / Series A / Jun 30, 2025 | |
DeepUll
|
DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise. | $56.9M / Series C / Apr 29, 2025 | |
Proton Intelligence
|
Proton Intelligence provides biomarker monitoring to manage chronic disease and save lives. The first biomarker is potassium, targeting hyperkalemia in chronic kidney disease (CKD) patients who have additional co-morbidities ProtonIntel was founded in 2020 and was headquartered in Vancouver, Canada. | $7M / Seed / Dec 24, 2024 | |
Capitainer
|
Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $1.4M / Series A / Feb 15, 2024 | |
Zetta Genomics
|
Zetta Genomics manages large-scale genomic data for precision medicine. The company employs distributed database technology and best practice security techniques to leverage genomic data benefits while preserving data privacy. Zetta Genomics was founded in 2018 and is based in Cambridge, England. | $2.3M / Seed / Feb 08, 2024 | |
OxCan
|
OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection. | $11M / Series A | |
|
OxCan
|
OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection. | $11M / Series A |
Co-Investors
Aurelium Ventures
2 deals together
Civilization Ventures
2 deals together
Cross-Border Impact Ventures
2 deals together
DigitalDx Ventures
2 deals together
Eka Ventures
2 deals together
Macmillan Cancer Support
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does We Venture Capital invest in?
We Venture Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did We Venture Capital last invest?
The most recent investment recorded for We Venture Capital closed in Jun 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
